Enanta Pharmaceuticals Inc (ENTA)
12.98
+0.31
(+2.45%)
USD |
NASDAQ |
Jun 28, 16:00
12.90
-0.08
(-0.62%)
After-Hours: 20:00
Enanta Pharmaceuticals Research and Development Expense (TTM): 151.11M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 151.11M |
| December 31, 2023 | 158.99M |
| September 30, 2023 | 163.52M |
| June 30, 2023 | 162.15M |
| March 31, 2023 | 158.26M |
| December 31, 2022 | 156.88M |
| September 30, 2022 | 164.52M |
| June 30, 2022 | 178.67M |
| March 31, 2022 | 186.58M |
| December 31, 2021 | 186.00M |
| September 30, 2021 | 174.11M |
| June 30, 2021 | 161.85M |
| March 31, 2021 | 149.54M |
| December 31, 2020 | 140.64M |
| September 30, 2020 | 136.76M |
| June 30, 2020 | 138.79M |
| March 31, 2020 | 138.57M |
| December 31, 2019 | 140.11M |
| September 30, 2019 | 142.21M |
| June 30, 2019 | 130.42M |
| March 31, 2019 | 124.44M |
| December 31, 2018 | 111.77M |
| September 30, 2018 | 94.86M |
| June 30, 2018 | 84.45M |
| Date | Value |
|---|---|
| March 31, 2018 | 71.37M |
| December 31, 2017 | 62.89M |
| September 30, 2017 | 57.45M |
| June 30, 2017 | 52.44M |
| March 31, 2017 | 47.82M |
| December 31, 2016 | 43.95M |
| September 30, 2016 | 40.46M |
| June 30, 2016 | 36.01M |
| March 31, 2016 | 31.48M |
| December 31, 2015 | 27.70M |
| September 30, 2015 | 23.19M |
| June 30, 2015 | 21.34M |
| March 31, 2015 | 19.64M |
| December 31, 2014 | 19.00M |
| September 30, 2014 | 18.74M |
| June 30, 2014 | 17.84M |
| March 31, 2014 | 17.32M |
| December 31, 2013 | 16.31M |
| September 30, 2013 | 16.84M |
| June 30, 2013 | 16.80M |
| March 31, 2013 | 17.68M |
| December 31, 2012 | 17.24M |
| September 30, 2012 | 15.12M |
| June 30, 2012 | 13.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
136.76M
Minimum
Sep 2020
186.58M
Maximum
Mar 2022
157.33M
Average
158.26M
Median
Mar 2023
Research and Development Expense (TTM) Benchmarks
| Artivion Inc | 28.43M |
| Nanoviricides Inc | 7.168M |
| FibroGen Inc | 246.77M |
| Corvus Pharmaceuticals Inc | 16.01M |
| Bioventus Inc | 12.27M |